Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019 Jan 07;: Authors: Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL Abstract BACKGROUND & AIMS: There is evidence that it is safe and effective for patients with inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original infliximab drug to a biosimilar, but little is known about outcomes of reverse…

Read More

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease but Not Ulcerative Colitis.

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease but Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan 05;: Authors: Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE,…

Read More

Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis.

Related Articles Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 Oct 26;: Authors: Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ Abstract BACKGROUND & AIMS: Therapeutic drug monitoring might be used to personalize infliximab treatment of patients with ulcerative colitis (UC), although exposure thresholds associated with endoscopic healing are uncertain. We aimed to determine infliximab concentration thresholds associated with endoscopic outcomes during induction and maintenance therapy for patients with UC. METHODS: We analyzed data from 484 patients…

Read More

Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis.

Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2019 Jan 04;: Authors: Borren NZ, Ananthakrishnan AN Abstract BACKGROUND & AIMS: Management of immune-mediated inflammatory diseases often requires lifelong immunosuppression. Increasing numbers of older patients have inflammatory diseases and are particularly vulnerable to risks of immune suppressive therapies-particularly infections and malignancies. METHODS: We systematically searched PubMed/Medline and Embase to identify eligible studies that examined the safety of biologic therapies in older patients with immune-mediated inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis,…

Read More

Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals.

Related Articles Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals. Clin Gastroenterol Hepatol. 2018 Nov 21;: Authors: Pittet V, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P Abstract BACKGROUND & AIMS: Inflammatory bowel disease (IBD) scoring systems combine patient-reported data with physicians’ observations to determine patient outcomes, but these systems are believed to have limitations. We used real-world data from a large IBD cohort in Switzerland to compare results between patients and healthcare professionals’ from scoring systems for Crohn’s disease (CD)…

Read More

Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis-a Systematic Review.

Related Articles Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis-a Systematic Review. Clin Gastroenterol Hepatol. 2018 Dec 21;: Authors: Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL Abstract BACKGROUND & AIMS: Optimal management of patients with ulcerative colitis (UC) requires assessment of disease activity-usually by endoscopy, which is invasive, costly, and not risk free. We performed a systematic review to determine whether clinical symptoms correlate with findings from endoscopy assessments of patients with UC. METHODS:…

Read More

Preventive Medicine in Inflammatory Bowel Disease.

Related Articles Preventive Medicine in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 Dec 06;: Authors: Weaver KN, Long MD Abstract The prevalence of inflammatory bowel disease (IBD) is increasing worldwide. The therapeutic options available to our patients are also increasing. These therapies offer patients the prospect of clinical and endoscopic remission, as well as improved quality of life. However, the management of IBD has become complex, including identification of specific risks associated with IBD and its therapies. The provider needs to consider forms of primary, secondary and tertiary prevention in…

Read More

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

Related Articles Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2018 Nov 23;: Authors: Sandborn WJ, Panés J, D’Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G Abstract BACKGROUND & AIMS: Tofacitinib is an oral, small-molecule inhibitor of JAK approved in several countries for the treatment of ulcerative colitis (UC). We report integrated safety analyses of tofacitinib-treated patients with moderate to severe UC. METHODS: Patients receiving placebo or…

Read More

Obesity and Weight Gain Since Early Adulthood are Associated With a Lower Risk of Microscopic Colitis.

Related Articles Obesity and Weight Gain Since Early Adulthood are Associated With a Lower Risk of Microscopic Colitis. Clin Gastroenterol Hepatol. 2018 Dec 06;: Authors: Liu PH, Burke KE, Ananthakrishnan AN, Lochhead P, Olen O, Ludvigsson JF, Richter JM, Chan AT, Khalili H Abstract BACKGROUND & AIMS: Obesity promotes intestinal inflammation and might contribute to the pathogenesis of inflammatory bowel disease. We examined the association between obesity and risk of microscopic colitis in a prospective cohort study. METHODS: We collected data from 192,101 women enrolled in the Nurses’ Health Study…

Read More

Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab.

Related Articles Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol. 2018 Dec 07;: Authors: Ma C, Kotze PG, Almutairdi A, Jairath V, Panaccione R PMID: 30528845 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30528845?dopt=Abstract

Read More
<< Go Back